Global Liver Institute Welcomes Larry R. Holden as CEO
September 03, 2024 09:54 ET
|
Global Liver Institute
Washington, DC, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the...
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population
March 14, 2024 17:18 ET
|
Global Liver Institute
Washington, DC, March 14, 2024 (GLOBE NEWSWIRE) -- Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication...
Sonic Incytes Medical Corp. Successfully Completes Series A Raise of US$7.3M to Accelerate Velacur™ Commercialization
December 07, 2021 10:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp., a health technology company focused on liver health, is pleased to announce the completion of its US$7.3M...
Velacur™ Data Presented at 2021 AASLD The Liver Meeting®
November 12, 2021 08:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corp. is pleased to announce that data from its sponsored clinical study of VelacurTM – the first handheld 3D liver health...
Sonic Incytes Showcases Velacur™ at ACG 2021
October 13, 2021 10:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- In recognition of Liver Awareness Month this October, Sonic Incytes Medical Corp. is pleased to showcase VelacurTM, the first handheld...
Sonic Incytes Announces FDA Clearance and US Launch of Velacur™ to Help Manage Emerging Health Crisis
October 20, 2020 10:00 ET
|
Sonic Incytes Medical Corp.
VANCOUVER, British Columbia, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Sonic Incytes Medical Corporation is pleased to announce the US commercial release of VelacurTM, the world’s first handheld 3D liver...